Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
A man in his late 20s was diagnosed with BRAF V600E-mutated cutaneous melanoma of the left knee (T3a) and underwent wide local excision.One year later, he had a solitary local recurrence resected and received 12 months of adjuvant dabrafenib and trametinib.Seven months after completion of adjuvant therapy, he developed headaches and a right visual field deficit.Magnetic resonance imaging (MRI) revealed a solitary left occipital enhancing lesion.Subtotal resection confirmed melanoma brain metastasis (MBM), and he initiated adjuvant ipilimumab/nivolumab, complicated by Clostridiodies difficile colitis and subsequent immune-related colitis requiring corticosteroids and vedolizumab.Postoperative radiotherapy (RT) was completed.Six months later, he underwent stereotactic radiosurgery (SRS) to a new left putamen lesion (hereinafter referred to as basal ganglia lesion).Nivolumab was resumed but discontinued because of severe inflammatory arthritis requiring immunosuppression.The patient presented to our institution 6 months later.Positron emission tomography/computed tomography identified a new right thigh metastasis.MRI revealed apparent enlargement of the left occipital and basal ganglia lesions (Figure 1).Ipilimumab/nivolumab treatment was reinitiated but was complicated 3 months later by worsening right hemiparesis and hemianopia in the setting of hemorrhagic changes in both lesions.Stereotactic biopsy of the occipital lesion confirmed radiation necrosis.He subsequently developed acute worsening of right hemiparesis, and a lacunar infarct, attributed to mass effect on the lenticulostriate vessels, was identified.Given his biopsy-proven radiation necrosis and complete response of the right thigh metastasis, with no other systemic disease identified at the time, immunotherapy was discontinued (the last dose was received 3-4 weeks before biopsy).Three months after the biopsy, resection of the enlarging occipital lesion was performed in the setting of worsening hemianopia and again confirmed radiation necrosis.One month later, the basal ganglia lesion showed further hemorrhagic progression and enlarging nodular enhancement with worsening edema, headaches, and aphasia.Surgical re-resection was not recommended.Multidisciplinary review concluded that, although radiation necrosis could not be excluded, a focal nodular region of enhancement raised concern for active tumor progression.Given diagnostic uncertainty and the need for rapid intracranial disease control, the team initiated encorafenib/ binimetinib as the systemic therapy most likely to produce a prompt response and help distinguish tumor progression from radiation necrosis.Imaging 4 weeks later revealed reduced lesion size and edema.Over the following months, he was doing well clinically with only mild symptom burden and was able to work full time.After 7 months on targeted therapy, MRI revealed asymptomatic progression in the basal ganglia and a new occipital lesion, which was treated with hypofractionated stereotactic radiotherapy (SRT; 3800 centigrays in
Fields of Study & Subjects
Brain Metastases and Treatment
Cancer Immunotherapy and Biomarkers
Melanoma and MAPK Pathways
Publication details
- Journal / source
- CA A Cancer Journal for Clinicians
- Volume
- 76
- Issue
- 2
- Pages
- e70079–e70079
- Publication date
- 1 March 2026
- Language
- EN